In addition, the exploration in CD133 expression, a biomarker of GBM stem-like cells, using flow cytometry, demonstrated that the combinational therapy led to a three-fold reduction of CD133 expression compared to untreated spheroids. Here, PROM1 is linked to glioblastoma.